Avalo Therapeutics(AVTX) - 2025 Q3 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2025 | | | Name of each exchange on which | | --- | --- | --- | | Title of each class | Trading Symbol | registered | | Common Stock, $0.001 par value | AVTX | Nasdaq Capital Market | Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15( ...